TAK-788 is a potent and selective dual EGFR/HER2 tyrosine kinase inhibitor. Specifically, TAK-788 inhibited all 14 mutant variants of EGFR (IC50 values between 2.4 and 22 nM), and all 6 mutant variants of HER2 (IC50 values between 2.4 and 26 nM), more potently than it inhibited WT EGFR (IC50 value of 35 nM), including all 8 variants with exon 20 activating insertions.

KEYWORDS: TAK-788 | supplier | EGFR/HER2 inhibitor | Mobocertinib | AP32788 | TAK 788 | TAK788 | AP 32788 | AP-32788 | CAS [1847461-43-1] | Non Selective (Phosphorylation Substrates) | EGFR | ErbB2-HER2 | Inhibitor | Receptors | Non-small cell lung cancer |  NSCLC